Published in J Biol Chem on October 22, 2009
More effective nanomedicines through particle design. Small (2011) 1.80
Particle shape enhances specificity of antibody-displaying nanoparticles. Proc Natl Acad Sci U S A (2013) 1.63
Modulation of endothelial targeting by size of antibody-antioxidant enzyme conjugates. J Control Release (2010) 0.88
Lung vascular targeting using antibody to aminopeptidase P: CT-SPECT imaging, biodistribution and pharmacokinetic analysis. J Vasc Res (2010) 0.87
Site-specific biotinylation of purified proteins using BirA. Methods Mol Biol (2015) 0.86
NCI Image-Guided Drug Delivery Summit. Cancer Res (2011) 0.83
Construction of metabolically biotinylated adenovirus with deleted fiber knob as targeting vector. Virol J (2010) 0.75
Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol (2004) 36.25
High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res (2002) 6.64
A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation. Protein Sci (1999) 6.05
Avidin and streptavidin. Methods Enzymol (1990) 5.47
A monovalent streptavidin with a single femtomolar biotin binding site. Nat Methods (2006) 3.89
Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol (2007) 3.54
Biotination of proteins in vivo. A post-translational modification to label, purify, and study proteins. J Biol Chem (1990) 3.48
Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature (2004) 3.24
Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol (2000) 2.73
Screening for receptor ligands using large libraries of peptides linked to the C terminus of the lac repressor. Proc Natl Acad Sci U S A (1992) 2.67
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol (2005) 2.55
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol (2007) 2.53
Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol (1997) 2.13
Acetylcholine-induced calcium signaling and contraction of airway smooth muscle cells in lung slices. J Gen Physiol (2002) 1.82
Caveolae: mining little caves for new cancer targets. Nat Rev Cancer (2003) 1.76
Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm (2000) 1.65
Design of multivalent complexes using the barnase*barstar module. Nat Biotechnol (2003) 1.65
Selective immobilization of proteins to self-assembled monolayers presenting active site-directed capture ligands. Proc Natl Acad Sci U S A (2002) 1.63
New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology (1997) 1.61
Recombinant protein production by large-scale transient gene expression in mammalian cells: state of the art and future perspectives. Biotechnol Lett (2007) 1.52
An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. Gene (1997) 1.50
Genetically engineered avidins and streptavidins. Cell Mol Life Sci (2006) 1.49
Screening phage display libraries for organ-specific vascular immunotargeting in vivo. Proc Natl Acad Sci U S A (2005) 1.46
Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Proc Natl Acad Sci U S A (2002) 1.43
Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sin (2005) 1.32
Method for generation of in vivo biotinylated recombinant antibodies by yeast mating. J Immunol Methods (2006) 1.32
Brave new (strept)avidins in biotechnology. Trends Biotechnol (2007) 1.29
Breaking the one antibody-one target axiom. Proc Natl Acad Sci U S A (2006) 1.26
Transient gene expression in suspension HEK-293 cells: application to large-scale protein production. Biotechnol Prog (2005) 1.22
Vascular targeting as a strategy for cancer therapy. N Engl J Med (1998) 1.14
Single chain Fab (scFab) fragment. BMC Biotechnol (2007) 1.12
Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. Br J Cancer (1998) 1.10
The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity. Clin Cancer Res (2007) 1.10
Deimmunization of monoclonal antibodies. Methods Mol Biol (2009) 1.02
Large-scale transfection of mammalian cells for the fast production of recombinant protein. Mol Biotechnol (2006) 0.99
Metabolic biotinylation of recombinant antibody by biotin ligase retained in the endoplasmic reticulum. Biomol Eng (2007) 0.99
Self-assembled "dock and lock" system for linking payloads to targeting proteins. Bioconjug Chem (2006) 0.97
Analysis of IgG heavy chain to light chain ratio with mutant Encephalomyocarditis virus internal ribosome entry site. Protein Eng Des Sel (2007) 0.96
Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody. Br J Cancer (1996) 0.96
Streptabody, a high avidity molecule made by tetramerization of in vivo biotinylated, phage display-selected scFv fragments on streptavidin. Mol Immunol (2000) 0.93
A versatile system for site-specific enzymatic biotinylation and regulated expression of proteins in cultured mammalian cells. Protein Expr Purif (2006) 0.93
In vitro enzymatic biotinylation of recombinant fab fragments through a peptide acceptor tail. Bioconjug Chem (1999) 0.89
Generation and characterization of a novel single-gene-encoded single-chain immunoglobulin molecule with antigen binding activity and effector functions. Mol Immunol (1999) 0.86
Molecular vehicle for target-mediated delivery of therapeutics and diagnostics. J Control Release (2001) 0.80
Fluorometric assay for quantitation of biotin covalently attached to proteins and nucleic acids. Biotechniques (2007) 0.78
Linear gene fusions of antibody fragments with streptavidin can be linked to biotin labelled secondary molecules to form bispecific reagents. Biochem Mol Biol Int (1997) 0.77
An interaction between S*tag and S*protein derived from human ribonuclease 1 allows site-specific conjugation of an enzyme to an antibody for targeted drug delivery. J Immunol Methods (2005) 0.77
Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol (2007) 3.54
Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature (2004) 3.24
Label-free, normalized quantification of complex mass spectrometry data for proteomic analysis. Nat Biotechnol (2009) 3.01
Direct proteomic mapping of the lung microvascular endothelial cell surface in vivo and in cell culture. Nat Biotechnol (2004) 2.98
Caveolae: mining little caves for new cancer targets. Nat Rev Cancer (2003) 1.76
A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature. J Clin Invest (2006) 1.62
Recruitment of endothelial caveolae into mechanotransduction pathways by flow conditioning in vitro. Am J Physiol Heart Circ Physiol (2003) 1.47
Screening phage display libraries for organ-specific vascular immunotargeting in vivo. Proc Natl Acad Sci U S A (2005) 1.46
Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Proc Natl Acad Sci U S A (2002) 1.43
Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: a role for phosphatidylinositol 3'-kinase. Cancer Res (2002) 1.35
Calcium-dependent membrane association sensitizes soluble guanylyl cyclase to nitric oxide. Nat Cell Biol (2002) 1.21
Overcoming in vivo barriers to targeted nanodelivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 1.10
Interaction of the hepatitis B core antigen and the innate immune system. J Immunol (2009) 1.05
Impaired tumor growth, metastasis, angiogenesis and wound healing in annexin A1-null mice. Proc Natl Acad Sci U S A (2009) 1.00
Enhancing identifications of lipid-embedded proteins by mass spectrometry for improved mapping of endothelial plasma membranes in vivo. Mol Cell Proteomics (2009) 0.99
Neutral sphingomyelinase inhibitor scyphostatin prevents and ceramide mimics mechanotransduction in vascular endothelium. Am J Physiol Heart Circ Physiol (2004) 0.97
Application of capture-recapture models to estimation of protein count in MudPIT experiments. Anal Chem (2006) 0.96
T cell pathways involving CTLA4 contribute to a model of acute lung injury. J Immunol (2010) 0.94
A selective tumor microvasculature thrombogen that targets a novel receptor complex in the tumor angiogenic microenvironment. Cancer Res (2005) 0.93
Growth suppression by a p14(ARF) exon 1beta adenovirus in human tumor cell lines of varying p53 and Rb status. Cancer Gene Ther (2002) 0.93
Immunotargeting and cloning of two CD34 variants exhibiting restricted expression in adult rat endothelia in vivo. Am J Physiol Lung Cell Mol Physiol (2009) 0.92
Enhanced tumor suppression by a p14ARF/p53 bicistronic adenovirus through increased p53 protein translation and stability. Cancer Res (2003) 0.91
Transient mechanoactivation of neutral sphingomyelinase in caveolae to generate ceramide. J Biol Chem (2002) 0.90
Role of caveolae and lipid rafts in cancer: workshop summary and future needs. Cancer Res (2003) 0.90
Iodine-125 radiolabeling of silver nanoparticles for in vivo SPECT imaging. Int J Nanomedicine (2010) 0.90
Suppression of tumor growth by designed dimeric epidithiodiketopiperazine targeting hypoxia-inducible transcription factor complex. J Am Chem Soc (2013) 0.89
Genomics and proteomics of lung disease: conference summary. Am J Physiol Lung Cell Mol Physiol (2007) 0.88
Assessing the barriers to image-guided drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.86
Cooperative effect between immunotherapy and antiangiogenic therapy leads to effective tumor rejection in tolerant Her-2/neu mice. Cancer Res (2003) 0.85
Overcoming key technological challenges in using mass spectrometry for mapping cell surfaces in tissues. Mol Cell Proteomics (2010) 0.84
Endothelin induces rapid, dynamin-mediated budding of endothelial caveolae rich in ET-B. J Biol Chem (2012) 0.84
Ubiquitous yet distinct expression of podocalyxin on vascular surfaces in normal and tumor tissues in the rat. J Vasc Res (2009) 0.83
Caveolae and cancer. Recent Results Cancer Res (2010) 0.82
Targeting and imaging signature caveolar molecules in lungs. Proc Am Thorac Soc (2009) 0.81
The combination of plumbagin with androgen withdrawal causes profound regression of prostate tumors in vivo. Prostate (2012) 0.80
Streamlining biomarker discovery. Nat Biotechnol (2011) 0.79
Chapter 8. Proteomic mapping of the vascular endothelium in vivo for vascular targeting. Methods Enzymol (2008) 0.79
Methods for delivery of adenoviral vectors to tumor vasculature. Hum Gene Ther (2007) 0.77
Range Charts for Agreement in Measurement Comparison Studies, With Application to Replicate Mass Spectrometry Experiments. J Proteomics Bioinform (2008) 0.76
Systems analysis of endothelial cell plasma membrane proteome of rat lung microvasculature. Proteome Sci (2011) 0.76
Laser-targeted photosensitizer-induced lung injury: noninvasive rat model of pulmonary infarction. Exp Lung Res (2011) 0.76
Experimental model of transthoracic, vascular-targeted, photodynamically induced myocardial infarction. Am J Physiol Heart Circ Physiol (2013) 0.75
Tumor targeting, trifunctional dendritic wedge. Bioconjug Chem (2014) 0.75
Construction of metabolically biotinylated adenovirus with deleted fiber knob as targeting vector. Virol J (2010) 0.75